Desmoid Tumor Highlights From CTOS 2024

CME

Independent Conference Highlights of the 2024 CTOS Annual Meeting: Perspectives on Emerging Data in Desmoid Tumors

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: February 20, 2025

Expiration: August 19, 2025

Activity

Progress
1 2
Course Completed

Introduction

In this text-based module, Ravin Ratan, MD, summarizes 5 key studies on desmoid tumors (DTs) presented at the 2024 Connective Tissue Oncology Society Annual Meeting (CTOS 2024): long-term and subgroup analyses of the phase III DeFi trial; a real-world study of nirogacestat; a population-based study of pegylated liposomal doxorubicin (PLD); and a study of a multidisciplinary approach to treatment. 

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

Which of the following clinical outcomes with nirogacestat was reported in the long-term follow-up of the phase III DeFi trial in patients with progressive DTs?

A 28-year-old woman experiencing moderate pain in her shoulder region that did not abate with over-the-counter nonsteroidal anti-inflammatory drugs was diagnosed with a DT and comes to discuss next steps. Her tumor measures 8 cm in size and genetic testing reveals theT41A β-catenin mutation. What management strategy would you recommend for this patient?

How confident are you in discussing the clinical implications of new data and ongoing clinicals trials with your patients with DTs?